News
PRAX
--
0.00%
--
Praxis Precision Medicines Inc (PRAX) CFO Timothy Edwin Kelly Bought $76,069 of Shares
GuruFocus News · 09/03 12:15
Praxis Precision Medicines to Present at Citi's 16th Annual BioPharma Virtual Conference
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that ...
GlobeNewswire · 09/01 13:00
BofA Initiates Praxis Precision Medical At Buy
Praxis Precision Medicines Inc’s (NASDAQ: PRAX) lead asset has demonstrated encouraging data for central nervous system diseases and has a broad pipeline that targets both prevalent and rare disorders, according to BofA Securities.
Benzinga · 08/26 17:01
Clinicaltrials.gov Site Shows Praxis Precision Medicines Study 'A Clinical Trial of 3 Doses of PRAX-944 in Participants With Essential Tremor' Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05021991
Benzinga · 08/26 13:33
B of A Securities Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $28
B of A Securities initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $28.
Benzinga · 08/26 11:46
--BofA Securities Starts Praxis Precision Medicines at Buy With $28 Price Target
MT Newswires · 08/26 07:08
Triple-S Management, Bio-Path leads healthcare gainers; Theravance Biopharma, Vivos Therapeutics among major losers
Gainers: Triple-S Management (NYSE:GTS) +45%, Bio-Path (NASDAQ:BPTH) +21%, Reviva Pharmaceuticals (NASDAQ:RVPH) +21%, XTL Biopharmaceuticals (NASDAQ:XTLB) +13%, Protara Therapeutics (NASDAQ:TARA) +12%. Losers: Theravance Biopharma (NASDAQ:TBPH) -31%, Vivos...
Seekingalpha · 08/24 15:10
Praxis tops weekly healthcare gainers; Sesen Bio joins laggards for second consecutive week
Despite snapping a four-day rally on Wednesday, healthcare stocks in the S&P 500 gained for two consecutive sessions to end the week ~1.8% higher, outperforming the ~0.6% loss in the broader index. Among
Seekingalpha · 08/21 10:57
Praxis Precision Medicines Inc (PRAX) CEO Marcio Souza Bought $150,668 of Shares
GuruFocus News · 08/20 16:15
Artal Group S.A. Buys Generation Bio Co, AlloVir Inc, Biohaven Pharmaceutical Holding Co, Sells ...
GuruFocus News · 08/16 21:38
Praxis Unveils Perimenopausal Depression Trial Data
Benzinga · 08/16 14:33
--Wedbush Adjusts Praxis Precision Medicines PT to $50 From $55, Maintains Outperform Rating
MT Newswires · 08/16 13:39
BRIEF-Praxis Precision Medicines Reports Prax-114 Perimenopausal Depression (Pmd) Phase 2A Proof-Of-Concept Trial Results
reuters.com · 08/16 12:50
Praxis Precision Medicines Reports Positive Data From Trial of PRAX-114 to Treat Perimenopausal Depression
MT Newswires · 08/16 12:29
BRIEF-Praxis Precision Medicines Reports Q2 Loss Per Share $0.88
reuters.com · 08/16 12:25
Praxis Precision Medicine Q2 EPS $(0.88) Up From $(8.28) YoY
Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(0.88) per share. This is a 89.37 percent increase over losses of $(8.28) per share from the same period last year.
Benzinga · 08/16 12:20
Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression Phase 2a Proof-of-Concept Trial Results; Says 'PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms'
PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study   PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile CAMBRIDGE, Mass.,
Benzinga · 08/16 11:56
Praxis Precision Medicines Reports PRAX-114 Perimenopausal Depression (PMD) Phase 2a Proof-of-Concept Trial Results and Announces Plans to Advance to Phase 2b Study in Women with Menopausal and Mood Symptoms
PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Praxis Precis...
GlobeNewswire · 08/16 11:55
Praxis Precision Medicines Q2 Loss Per Share Narrows, Operating Expenses Up
MT Newswires · 08/16 09:34
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
Webull provides a variety of real-time PRAX stock news. You can receive the latest news about Praxis Precision Medicines, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. Its development stage products include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extrasynaptic-preferring gamma-aminobutyric acid-A (GABAA) receptor positive allosteric modulator (PAM) for the treatment of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channel, for the treatment of essential tremor (ET). PRAX-562 is the selective, persistent sodium current blocker in development for the treatment of a range of CNS disorders.